Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan
This article was originally published in The Tan Sheet
Executive Summary
The London firm announces Unicough cough/cold product’s launch after reviewing clinical trial results, but holds off on a Flarin ibuprofen launch until completing a trial. “We’re very, very pleased with this, although originally we wanted to be there slightly earlier,” says CEO Manfred Scheske.
You may also be interested in...
J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst
Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.
In Brief
Senate backs pre-tax OTC purchases; infirst Healthcare lands $38M investment; Star Scientific faces fraud allegation; Vitamin Shoppe franchise opens in Panama.
Congress Likely To Legislate Monetary Penalty Authority In FTC Enforcement If SCOTUS Strikes It
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: